Russia's R-Pharm in deals with AbbVie and Bristol-Myers for local production
US drugmaker AbbVie (NYSE: ABBV) has joined forces with Russia’s R-Pharm to establish the joint production of Kaletra (lopinavir/ritonavir), a drug for the treatment of HIV, reports The Pharma Letter’s local correspondent.
The project involves the launch of a full production cycle of the drug at the facilities of R-Pharm in Russia’s Yaroslavl. The volume of investments in the project is about $300 million. The project for the localization of Kaletra production in Russia has started in 2012 with the secondary packaging of the drug in Kostroma.
According to Larisa Kosse, AbbVie’s director of business and operations in Russia, commercial production of the drug will be started at the beginning of 2016.
R-Pharm to make Bristol-Myers’ Sprycel
Separately, Bristol-Myers Squibb (NYSE: BMY) and R-Pharm have concluded a license agreement on localization of production of Sprycel (dasatinib), an innovative drug for targeted antitumor therapy, at the R-Pharm facilities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze